Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats

T. Nabeshima, S. I. Ogawa, H. Nishimura, K. Fuji, T. Kameyama, Y. Sasaki

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Alzheimer's disease is characterized by the loss of cholinergic neurons in the nucleus basalis of Meynert and by a primary loss of memory function. Since staurosporine has been reported to induce differentiation in human neuroblastoma cells in vitro, we studied the effects of staurosporine on the amnesia induced by basal forebrain-lesion in rats. Staurosporine (0.05 and 0.1 mg/kg intraperitoneal) attenuated the impaired performance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion. This evidence indicates that neurotrophic factor-like substances may be used in novel therapeutic approaches to Alzheimer's disease.

Original languageEnglish
Pages (from-to)562-566
Number of pages5
JournalJournal of Pharmacology and Experimental Therapeutics
Volume257
Issue number2
Publication statusPublished - 01-01-1991

Fingerprint

Cholinergic Neurons
Staurosporine
Learning
Alzheimer Disease
Reversal Learning
Basal Nucleus of Meynert
Parietal Lobe
Choline O-Acetyltransferase
Amnesia
Memory Disorders
Nerve Growth Factors
Neuroblastoma
Basal Forebrain
Water
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

@article{700aecd45c8b40bda3e371e4c5849f99,
title = "Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats",
abstract = "Alzheimer's disease is characterized by the loss of cholinergic neurons in the nucleus basalis of Meynert and by a primary loss of memory function. Since staurosporine has been reported to induce differentiation in human neuroblastoma cells in vitro, we studied the effects of staurosporine on the amnesia induced by basal forebrain-lesion in rats. Staurosporine (0.05 and 0.1 mg/kg intraperitoneal) attenuated the impaired performance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion. This evidence indicates that neurotrophic factor-like substances may be used in novel therapeutic approaches to Alzheimer's disease.",
author = "T. Nabeshima and Ogawa, {S. I.} and H. Nishimura and K. Fuji and T. Kameyama and Y. Sasaki",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "257",
pages = "562--566",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. / Nabeshima, T.; Ogawa, S. I.; Nishimura, H.; Fuji, K.; Kameyama, T.; Sasaki, Y.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 257, No. 2, 01.01.1991, p. 562-566.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats

AU - Nabeshima, T.

AU - Ogawa, S. I.

AU - Nishimura, H.

AU - Fuji, K.

AU - Kameyama, T.

AU - Sasaki, Y.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Alzheimer's disease is characterized by the loss of cholinergic neurons in the nucleus basalis of Meynert and by a primary loss of memory function. Since staurosporine has been reported to induce differentiation in human neuroblastoma cells in vitro, we studied the effects of staurosporine on the amnesia induced by basal forebrain-lesion in rats. Staurosporine (0.05 and 0.1 mg/kg intraperitoneal) attenuated the impaired performance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion. This evidence indicates that neurotrophic factor-like substances may be used in novel therapeutic approaches to Alzheimer's disease.

AB - Alzheimer's disease is characterized by the loss of cholinergic neurons in the nucleus basalis of Meynert and by a primary loss of memory function. Since staurosporine has been reported to induce differentiation in human neuroblastoma cells in vitro, we studied the effects of staurosporine on the amnesia induced by basal forebrain-lesion in rats. Staurosporine (0.05 and 0.1 mg/kg intraperitoneal) attenuated the impaired performance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion. This evidence indicates that neurotrophic factor-like substances may be used in novel therapeutic approaches to Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0025880149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025880149&partnerID=8YFLogxK

M3 - Article

C2 - 2033505

AN - SCOPUS:0025880149

VL - 257

SP - 562

EP - 566

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -